企業概要
PDS Biotechnology Corporation operates as a clinical-stage biopharmaceutical entity focused on the development of a pipeline comprising targeted cancer immunotherapies. The company functions within the healthcare sector, specifically the biotechnology industry, where it advances therapeutic candidates intended for oncological applications. Its market capitalization stands at 5,526 万ドル (55.26 百万ドル), while the provided financial data lists annual revenue and employee count as unavailable (N/A). These valuation metrics indicate that the company is a small-cap entity with limited historical revenue data available for traditional scalability analysis, reflecting its status as an early-stage venture where value is derived from pipeline potential rather than current sales volume.
財務健全性
The company reported a net income of -3,449 万 5,504 ドル (34,495,504 ドル) and an EBITDA of -3,148 万 3,440 ドル (31,483,440 ドル) over the trailing twelve months, while revenue figures are not disclosed. The substantial negative net income relative to the EBITDA gap suggests significant non-operating expenses or one-time costs impacting the bottom line, as the gross margin, operating margin, and profit margin are all recorded at 0.0%. This indicates that the company has not yet generated profitable sales or that current revenue streams do not cover the direct costs of goods sold and operating expenses, resulting in a loss-making financial structure typical of clinical-stage firms. Free cash flow stands at -1,571 万 7,316 ドル (15,717,316 ドル), highlighting a consumption of cash reserves which limits immediate financial flexibility for external expansion without further capital raising. On the balance sheet, the company holds 2,671 万ドル (26.71 百万ドル) in cash against 1,693 万ドル (16.93 百万ドル) in debt, creating a net cash position, yet the debt-to-equity ratio is elevated at 182.94, suggesting a leveraged capital structure relative to its equity base. The current ratio is 2.98, indicating that the company possesses 2.98 times more current assets than current liabilities, which points to robust short-term liquidity despite the negative earnings. Furthermore, the Return on Equity (ROE) is -244.2% and the Return on Assets (ROA) is -52.0%, revealing that management effectiveness is currently measured by losses per unit of capital deployed rather than profit generation.
バリュエーション評価
The trailing twelve-month P/E ratio is not available (N/A), whereas the forward P/E ratio is listed as -1.84, implying that the market anticipates continued negative earnings in the near future rather than immediate profitability. The price-to-book ratio is -0.25, a negative figure indicating that the market capitalization is significantly below the company's book value, which often occurs when assets are carried at historical costs or when intangible assets dominate the balance sheet. The price-to-sales ratio and EV/EBITDA are also not available or negative (-1.44 for EV/EBITDA), suggesting that traditional valuation multiples based on earnings or sales are not applicable due to the company's current loss-making status. The stock has traded between a 52-week high of 1.92 ドル and a 52-week low of 0.51 ドル, meaning the current trading price sits somewhere within this range, reflecting high volatility common in small-cap biotech stocks. The beta value is 1.19, indicating that the stock's price volatility is 19% higher than the broader market, exposing investors to greater systematic risk compared to large-cap equities.
Growth & Income
Revenue growth and earnings growth rates over the year-over-year period are not available (N/A) in the current dataset, preventing a direct comparison of whether earnings are growing faster or slower than revenue. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, which means the company reinvests all available earnings or capital into research and development rather than distributing income to shareholders. The absence of a dividend policy is consistent with the firm's life cycle stage, where capital retention is prioritized to fund clinical trials and regulatory processes for Versamune HPV. Overall, the growth and income profile is characterized by a complete reliance on capital markets for funding, with zero current income distribution and undefined historical growth metrics.